Cat Cancer Genetics Mirror Humans
The first large-scale genetic survey of feline cancers, published in Science, found that the TP53 "guardian" gene is frequently mutated in both cat and human tumors. Researchers say successful treatments against specific genetic mutations in cats may translate directly to human cancer therapies.
- The international study involved sequencing DNA from 493 cat tumor samples across 13 different cancer types, creating the first large-scale genetic map of feline cancer. - The TP53 gene was the most frequently mutated gene found, appearing in 33% of all feline tumors studied, a rate nearly identical to the 34% seen in human cancers. - Researchers identified striking similarities in aggressive mammary cancers; over half of the feline mammary tumors had mutations in the *FBXW7* gene, a mutation linked to a worse prognosis in human breast cancer. - Laboratory tests on feline breast cancer cells with *FBXW7* mutations showed they were more sensitive to a class of chemotherapy drugs known as vinca alkaloids, which are already used in humans. - Cats are considered excellent models for human cancer because they live in the same environments, are exposed to similar carcinogens, and develop tumors spontaneously, unlike laboratory mice. - The genetic parallels extend to cancers of the blood, bone, lungs, skin, and central nervous system, reinforcing the "One Health" concept where veterinary and human medicine inform each other. - The research has produced a freely available database of the feline cancer genomes, creating a significant resource for the global scientific community to advance cancer research in both species. - This type of comparative oncology allows for a two-way flow of information; successful human therapies can be trialed in cats with similar genetic mutations, and data from feline clinical trials could inform human drug development.
